Hero image with Pittsburgh background pittplusme.org/study/1599

STUDY BASICS

Do you have a diagnosis of metastatic castration-resistant prostate cancer? If so, you may be interested in this study that will help researchers determine whether adding a study drug, called talazoparib, to an existing prostate cancer drug, called enzalutamide, provides any additional benefit to patients when compared to taking enzalutamide with a placebo (no medication).


IRB:
  SSU00094499 - Pfizer-C3441021, A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (Pro00025895)

Age Range
AGE:   18 and up

Duration DURATION:  Indefinite
VISITS:  Multiple

Location LOCATION: 
UPMC Cancer Centers in: Shadyside, Altoona, Arnold Palmer – Greensburg, Monroeville East, Northwest, Passavant, Uniontown, Upper St. Clair, Washington
Compensation COMPENSATION: 

None

Phone Number PHONE NUMBER:
1-866-438-8230
I'M INTERESTED
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1599
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet